In conclusion, our study suggests that for patients with advanced NSCLC with EGFR mutations and PD-L1 TPS ≥ 50% who have failed prior EGFR-TKI therapies without T790M mutation, ICI-based treatment could provide more favorable survival than classical chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.